X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12340) 12340
Book Review (2472) 2472
Publication (884) 884
Conference Proceeding (39) 39
Book Chapter (21) 21
Magazine Article (18) 18
Book / eBook (13) 13
Dissertation (7) 7
Paper (6) 6
Web Resource (4) 4
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11658) 11658
humans (9004) 9004
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (6205) 6205
male (5250) 5250
animals (4903) 4903
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (4538) 4538
statins (4364) 4364
pharmacology & pharmacy (3922) 3922
female (3657) 3657
middle aged (2645) 2645
simvastatin (2321) 2321
cholesterol (2200) 2200
aged (2117) 2117
rats (1973) 1973
atorvastatin (1821) 1821
adult (1625) 1625
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (1388) 1388
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (1384) 1384
simvastatin - pharmacology (1379) 1379
cardiac & cardiovascular systems (1333) 1333
pravastatin (1302) 1302
mice (1287) 1287
risk factors (1265) 1265
atorvastatin calcium (1238) 1238
hydroxymethylglutaryl-coa reductase inhibitors (1204) 1204
atherosclerosis (1201) 1201
cells, cultured (1070) 1070
heptanoic acids - pharmacology (1041) 1041
peripheral vascular disease (1035) 1035
pyrroles - pharmacology (1021) 1021
dose-response relationship, drug (997) 997
treatment outcome (988) 988
hypercholesterolemia - drug therapy (974) 974
lovastatin - pharmacology (959) 959
lipids (952) 952
statin (947) 947
risk (946) 946
biochemistry & molecular biology (941) 941
abridged index medicus (927) 927
hmg-coa reductase (927) 927
cholesterol, ldl - blood (926) 926
hydroxymethylglutaryl coa reductases - metabolism (915) 915
analysis (910) 910
hypercholesterolemia (899) 899
therapy (878) 878
cholesterol - blood (876) 876
prevention (856) 856
lovastatin (842) 842
coronary-heart-disease (833) 833
coa reductase inhibitors (831) 831
expression (782) 782
inflammation (773) 773
anticholesteremic agents - pharmacology (768) 768
drug therapy (737) 737
time factors (734) 734
antilipemic agents (727) 727
research (720) 720
drug interactions (710) 710
disease (672) 672
nitric-oxide synthase (669) 669
cardiovascular diseases - prevention & control (648) 648
cardiovascular disease (642) 642
rosuvastatin (637) 637
medicine & public health (626) 626
in-vitro (622) 622
pravastatin - pharmacology (622) 622
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (620) 620
cholesterol - metabolism (617) 617
rats, sprague-dawley (617) 617
rosuvastatin calcium (617) 617
anticholesteremic agents - therapeutic use (612) 612
drug therapy, combination (608) 608
disease models, animal (599) 599
coenzyme-a reductase (594) 594
oxidative stress (590) 590
c-reactive protein (588) 588
cardiovascular-disease (562) 562
lipids - blood (561) 561
health aspects (559) 559
cardiovascular diseases (556) 556
apoptosis (547) 547
mortality (542) 542
myocardial-infarction (538) 538
pharmacology (537) 537
simvastatin - therapeutic use (537) 537
cell line (535) 535
endothelium, vascular - drug effects (535) 535
care and treatment (534) 534
aged, 80 and over (531) 531
enzymes (516) 516
heptanoic acids - therapeutic use (502) 502
metabolism (501) 501
pyrroles - therapeutic use (498) 498
liver - metabolism (489) 489
rats, wistar (482) 482
cholesterol - biosynthesis (481) 481
internal medicine (479) 479
physiological aspects (479) 479
hyperlipidemias - drug therapy (477) 477
low-density-lipoprotein (476) 476
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12000) 12000
Japanese (85) 85
French (56) 56
Spanish (48) 48
Russian (35) 35
German (33) 33
Chinese (31) 31
Polish (22) 22
Hungarian (17) 17
Italian (16) 16
Dutch (8) 8
Finnish (5) 5
Czech (4) 4
Portuguese (4) 4
Hebrew (3) 3
Romanian (2) 2
Turkish (2) 2
Bosnian (1) 1
Croatian (1) 1
Danish (1) 1
Norwegian (1) 1
Serbian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL INVESTIGATION, ISSN 0021-9738, 08/2001, Volume 108, Issue 3, pp. 399 - 405
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2012, Volume 60, Issue 19, pp. 1888 - 1898
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 07/2014, Volume 130, Issue 1, pp. 27 - 34
Background-Hutchinson-Gilford progeria syndrome is an ultrarare segmental premature aging disease resulting in early death from heart attack or stroke. There... 
Prenylation | Lonafarnib | Progeria | Atherosclerosis | Aging | Lamins | Kaplan-Meier estimate | atherosclerosis | SYNDROME MUTATION | LONG-TERM | FARNESYLTRANSFERASE INHIBITOR | CARDIAC & CARDIOVASCULAR SYSTEMS | lamins | PROTEIN | lonafarnib | PHENOTYPE | progeria | ZOLEDRONIC ACID | MOUSE MODEL | DISEASE | prenylation | PERIPHERAL VASCULAR DISEASE | aging | OF-THE-LITERATURE | MUTANT LAMIN-A | Atherosclerosis - genetics | Humans | Alkyl and Aryl Transferases - antagonists & inhibitors | Child, Preschool | Male | Young Adult | Piperidines - pharmacology | Nuclear Proteins - deficiency | Diphosphonates - therapeutic use | Imidazoles - therapeutic use | Child | Pravastatin - therapeutic use | Multicenter Studies as Topic - statistics & numerical data | Piperidines - administration & dosage | Progeria - mortality | Pyridines - administration & dosage | Lamin Type A | Genotype | Diphosphonates - administration & dosage | Imidazoles - pharmacology | Protein Precursors - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Pravastatin - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Adolescent | Progeria - complications | Cohort Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Clinical Trials as Topic - statistics & numerical data | Imidazoles - administration & dosage | Cause of Death | Progeria - drug therapy | Atherosclerosis - etiology | Genes, Dominant | Adult | Female | Drug Therapy, Combination | Nuclear Proteins - genetics | Pyridines - therapeutic use | Pravastatin - pharmacology | Protein Prenylation - drug effects | Protein Precursors - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Nuclear Proteins - metabolism | Treatment Outcome | Protein Precursors - deficiency | Piperidines - therapeutic use | Dimethylallyltranstransferase - antagonists & inhibitors | Pyridines - pharmacology | Atherosclerosis - prevention & control | Diphosphonates - pharmacology | Care and treatment | Usage | Enzyme inhibitors | Patient outcomes | Genetic aspects | Health aspects | Index Medicus | Abridged Index Medicus | farnesylation | lamin | Hutchinson-Gilford progeria syndrome | FTI
Journal Article
Journal Article
by Lee, S.J and Lee, I and Lee, J and Park, C and Kang, W.K
British Journal of Cancer, ISSN 0007-0920, 07/2014, Volume 111, Issue 3, pp. 497 - 505
Journal Article
Journal Article
Journal Article
Hypertension, ISSN 0194-911X, 08/2007, Volume 50, Issue 2, pp. 377 - 383
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 513, Issue 7519, pp. 507 - 511
Gain-of-function mutations in the fibroblast growth factor receptor 3 gene (FGFR3) result in skeletal dysplasias, such as thanatophoric dysplasia and... 
APOPTOSIS | ACHONDROPLASIA | ACTIVATION | MULTIDISCIPLINARY SCIENCES | GROWTH-FACTOR RECEPTOR-3 | MICE | MUTATIONS | DWARFISM | EXPRESSION | PEPTIDE | CARTILAGE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Chondrocytes - cytology | Lovastatin - pharmacology | Cartilage - pathology | Achondroplasia - pathology | Male | Cartilage - drug effects | Fluorobenzenes - administration & dosage | Thanatophoric Dysplasia - pathology | Fluorobenzenes - pharmacology | Receptor, Fibroblast Growth Factor, Type 3 - deficiency | Cartilage - cytology | Female | Cell Differentiation | Induced Pluripotent Stem Cells - cytology | Achondroplasia - drug therapy | Thanatophoric Dysplasia - genetics | Achondroplasia - genetics | Disease Models, Animal | Induced Pluripotent Stem Cells - pathology | Lovastatin - therapeutic use | Chondrocytes - pathology | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Bone Development - drug effects | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Phenotype | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Thanatophoric Dysplasia - drug therapy | Mice | Fluorobenzenes - therapeutic use | Sulfonamides - administration & dosage | Achondroplasia | Radiography | Care and treatment | Usage | Analysis | Diagnosis | Protein kinases | Genotype & phenotype | Transcription factors | Disease | Mutation | Kinases | Patients | Statins | Index Medicus
Journal Article